OncoMatch/Clinical Trials/NCT07026279
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Is NCT07026279 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including narmafotinib ascending doses and narmafotinib dose comparison for pancreatic cancer metastatic.
Treatment: narmafotinib ascending doses · narmafotinib dose comparison — This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts. Part A will test increasing dose levels of narmafotinib in at least 3 people per dose at up to 4 dose levels to assess safety. Part B will test 2 of the dose levels from Part A in 20 people per dose, to select the best dose to take forward into future studies. Participants will take narmafotinib as oral capsules every day. They will also receive mFOLFIRINOX chemotherapy on Day 1 and and Day 15 of 28-day cycles.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Confirmed diagnosis of metastatic pancreatic adenocarcinoma (PDAC) ... Have measurable disease by RECIST v1.1.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational medicinal product
Have received any investigational medicinal product (IMP) within 30 days or 5 half-lives (whichever is longer) prior to Day -7.
Cannot have received: radiotherapy
Received previous radiotherapy ... for the treatment of metastatic disease.
Cannot have received: surgery
Received previous ... surgery ... for the treatment of metastatic disease.
Cannot have received: chemotherapy
Received previous ... chemotherapy ... for the treatment of metastatic disease.
Cannot have received: investigational therapy
Received previous ... investigational therapy for the treatment of metastatic disease.
Cannot have received: 5-FU based chemotherapy (cytotoxic doses)
Received cytotoxic doses of any 5-FU based chemotherapy.
Cannot have received: FAK inhibitor (narmafotinib)
Prior treatment with narmafotinib or other FAK inhibitor within the 2 years prior to screening.
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Irvine Chao Family Cancer Centre · Orange, California
- University of Florida Shands · Gainesville, Florida
- Icahn School of Medicine at Mount Sinai · New York, New York
- Cleveland Clinic · Cleveland, Ohio
- Vanderbilt University Medical Centre · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify